Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 11 — Should US states control drug prices?

Biotechnology
Simon Wentworth
4 March 2022
episode11-big

More on this story...

Pharmaceutical
The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?
10 February 2022
Biotechnology
The Pharma Letter Podcast — Episode 9 — The rise of AI in drug discovery
30 December 2021
Biotechnology
The Pharma Letter Podcast — Episode 8 — Why hasn't the world embraced Sputnik V?
14 December 2021
Pharmaceutical
Will the unintended consequences of drug price transparency regulation outweigh its benefits?
18 March 2022


More ones to watch >


Today's issue

AstraZeneca sees progress in obesity drug trials, highlights new oral option
Pharmaceutical
AstraZeneca sees progress in obesity drug trials, highlights new oral option
5 November 2024
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Frits van Alphen gets Memo CDO job
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze